Press Releases Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Market Closed - Nasdaq Other stock markets 21:30:00 16/05/2024 BST			5-day change	1st Jan Change
2.76 ^USD	+2.22%		-4.50%	-4.50%

02-12	Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
02-07	Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	02-12	AQ
Acasti: Fiscal Q3 Earnings Snapshot	02-12	AQ
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	02-01	AQ
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	12-13	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-14	AQ
Acasti: Fiscal Q2 Earnings Snapshot	11-13	AQ
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	11-13	AQ
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	24/10/23	AQ
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial	23/10/23	AQ
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage	05/10/23	AQ
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)	04/10/23	AQ
Acasti Announces $7.5 Million Private Placement Equity Financing	26/09/23	AQ
Acasti to Participate in the H.C. Wainwright Global Investment Conference	06/09/23	AQ
Acasti Announces First Quarter 2024 Financial Results and Business Highlights	14/08/23	AQ
Acasti: Fiscal Q1 Earnings Snapshot	11/08/23	AQ
Acasti Announces First Quarter 2024 Financial Results and Business Highlights	11/08/23	AQ
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting	09/08/23	AQ
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients	10/07/23	PR
Acasti Pharma Announces 1-for-6 Reverse Stock Split	07/07/23	PR
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023	05/07/23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Press Releases

Filters